ArticleJournal of neuro-oncology2020
Female gender and exogenous progesterone exposition as risk factors for spheno-orbital meningiomas.
Article in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Association of hormone therapy with spheno-orbital meningiomas: bridging evidence and unknowns.Frontiers in oncology · 2026Pooled it
- From intraosseous meningioma and ossified metaplastic meningioma to osteomeningioma: a novel voxel-based, atlas-normalized MRI framework for the radiological classification of skull-involving meningiomas.Neuroimage. Reports · 2026Article
- Progestogen use and the risk of intracranial meningioma: a systematic review and meta-analysis.EClinicalMedicine · 2026Article
- Association of tumor locations, clinical manifestations, and histopathological grade in meningioma: a 10-year single-center study.Frontiers in oncology · 2026Article
- Depot Medroxyprogesterone Acetate and Risk of Meningioma in the US.JAMA neurology · 2025Article
- Paradoxical evolution of spheno-orbital meningioma after cessation of progestin treatment.Surgical neurology international · 2025Article
- Spheno-Orbital Meningiomas: The Rationale behind the Decision-Making Process of Treatment Strategy.Cancers · 2024Article
- Predictive factors of the postoperative proptosis recovery in surgery of spheno-orbital meningiomas.Acta neurochirurgica · 2024Article
- Implications of hormonal carcinogenesis for transgender and gender-diverse people undergoing gender-affirming hormone therapy: an up-to-date review.BMJ oncology · 2024Review
- Menopausal hormone therapy and central nervous system tumors: Danish nested case-control study.PLoS medicine · 2023Observational
- Hormone therapies in meningioma-where are we?Journal of neuro-oncology · 2023Review
- Risk of intracranial meningioma with three potent progestogens: A population-based case-control study.European journal of neurology · 2022Article
- Progestin-related WHO grade II meningiomas behavior-a single-institution comparative case series.Neurosurgical review · 2022Article
- Association of Hormonal Contraception with Meningioma Location in Indonesian Patients.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Are the clinical manifestations of CT scan and location associated with World Health Organization histopathological grades of meningioma?: A retrospective study.Annals of medicine and surgery (2012) · 2021Article
- Meningiomas and cyproterone acetate: a retrospective, monocentric cohort of 388 patients treated by surgery or radiotherapy for intracranial meningioma.Journal of neuro-oncology · 2021Article
- Prediction of meningioma shrinkage after cyproterone acetate cessation.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe great heterogeneity of meningiomas is challenging and we need to distinguish relevant subgroups. Spheno-orbital osteomeningiomas (SOOM) constitute a clinically specific entity, with slow-growing benign osteo-meningiomatous tumors, which recur after surgery in one fourth of cases. Neurosurgical daily practice, supported by the literature, shows that the vast majority of patients with SOOM are women, and we explored whether their epidemiological and hormonal profiles suggest a progesterone influence.
methodsWe retrospectively documented all radiologically and histologically confirmed cases of SOOM operated in 2005-2019 in our institution. We completed the clinical and hormone history by systematic telephone interviews.
resultsIn the literature, SOOM occur significantly more often in women than other meningiomas (749/847, 86.4% versus 73.8%, p = 0.002). Among 175 cases, we included 124 patients, 93.5% were women, younger than men (51 ± 5 versus 63 ± 8, p = 0.02). Women' meningiomas showed more progesterone receptors (96.4% versus 50%, p < 0.001). Exogenous hormonal intake, reliable in 82 cases, concerned 83.3% (64/78) of women, with frequent progesterone intake: 13 oestroprogestogenic treatment only, with old-generation progesterone analogs, 41 progesterone analogs (cyproterone acetate, nomegestrol acetate, chlormadinone, promegestone, etonogestrel, levonogestrel), 7 substitutive hormonal therapy for menopause, 3 others. Duration of treatment was 2-40 years, median 10 years.
conclusionsSOOM develop preferentially in women in their fifties, who often received progesterone analogs, and show progesterone receptors. Progesterone analogs are incriminated in skull base meningiomas, and this is the first report on the prevalence of exogenous hormone therapy specifically in SOOM. Whether SOOM reduce after treatment discontinuation, in particular the osteoma part, needs to be explored. Anti-progesterone treatments may represent an avenue for future research in soom.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.